GeoVax’s Novel Vaccine Platform Induces Both Antibody and T Cell Responses

Two major challenges in viral vector technologies are coding capacity – how much material can fit inside the vector – and manufacturing capabilities. GeoVax’s viral vector platform potentially overcomes both of those issues, enabling a broader immune system response and a manufacturing system able to quickly produce at scale and deliver vaccines successfully worldwide.